TerminatedNCT03149107
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Medication studyAges 18–40GermanySchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 40 years.
- Listed locations
- Mannheim and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 1, 2016
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 48
- Sponsor
- University Hospital, Bonn
- Sponsor type
- Hospital / academic medical center
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT03149107
- Official title
Show the full official title
Multimodal Prevention of First Psychotic Episode - a 2x2-Factorial Randomized Trial Investigating the Efficacy of Acetylcysteine and Integrated Preventive Psychological Intervention in Subjects Clinically at High Risk for Psychosis
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Mannheim · Tübingen · München
6 more locations
- Aachen
- Bonn
- Cologne
- Düsseldorf
- Alzey
- Berlin
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Hospital, Bonn, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including N-Acetylcysteine and Placebo.
Who can participate?
Listed age limits: 18 years to 40 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.